

Publications¹ for the Period 10/01/06 - 09/30/07

The Thoracic Oncology Program produced a total of 87 cancer-related publications from October 1, 2006 through September 30, 2007. Of these, 35 (40%) were inter-programmatic or inter- and intra-programmatic publications; 31 (36%) were intra-programmatic or inter- and intra-programmatic publications.

2006

- Bunn PA Jr (TOP)**. Can a single pill replace doublet chemotherapy in first-line therapy of advanced non-small cell lung cancer? *Clin Cancer Res* 12(20 Pt 1):5919-5920, 2006.
- * **Christiani DC, Pao W, DeMartini JC (TOP), Linnoila RI, Malkinson AM (CC,TOP), Onn A, Politi KA, Shap M, Wong KK**. BAC Consensus Conference, November 4-6, 2004: Epidemiology, pathogenesis, and preclinical models. *J Thorac Oncol* 1(9 Suppl):S2-S7, 2006.
- + **Coldren CD (TOP), Nick JA, Poch KR, Woolum MD, Fouty BW, O'Brien JM, Gruber MP, Zamora MR, Svetkauskaite D, Richter DA, He Q, Park JS, Overdier KH, Abraham E, Geraci MW (TOP)**. Functional and genomic changes induced by alveolar transmigration in human neutrophils. *Am J Physiol Lung Cell Mol Physiol* 291(6):L1267-L1276, 2006.
- Davies AM, Chansky K, Lau DH, Leigh BR, **Gaspar LE (TOP)**, Weiss GR, Wozniak AJ, Crowley JJ, Gandara DR. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. *J Clin Oncol* 24(33):5242-5246, 2006.
- Garfield D (TOP)**. Increasing osteoblastic lesions as a manifestation of a major response to gefitinib. *J Thorac Oncol* 1(8):859-860, 2006.
- Garfield D (TOP)**. Significance of the papillary subtype in relation to durable response to gefitinib in advanced non-small cell lung cancer. *Lung Cancer* 54(2):259, 2006.
- *+ **Helfrich BA, Raben D (TOP,DT), Varella-Garcia M (TOP), Gustafson D (DT), Chan DC (DT,TOP), Bemis L (CC), Coldren C (TOP), Baron A (DT), Zeng C, Franklin W (TOP), Hirsch FR (TOP,DT), Gazdar A, Minna J, Bunn PA Jr (TOP)**. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. *Clin Cancer Res* 12(23):7117-7125, 2006.
- *+ **Hirsch FR (TOP,DT), Varella-Garcia (TOP), Bunn PA Jr (TOP), Franklin WA (TOP)**, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flanner A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. *J Clin Oncol* 24(31):5034-5042, 2006.

¹ * = Inter-programmatic publication; + = intra-programmatic publication

Member names are highlighted and their respective programs are indicated in parentheses.

Program abbreviations: CB = Cell Biology; CC = Carcinogenesis and Chemoprevention; PC = AMC Cancer Prevention and Control; DT = Developmental Therapeutics; HRM = Hormone Related Malignancies; II = Immunology & Immunotherapy; MOP = Molecular Oncology Program; TOP = Thoracic Oncology Program

- Lara PN Jr, Chansky K, Davies AM, **Franklin WA (TOP)**, Gumerlock PH, Guaglianone PP, Atkins JN, Farneth N, Mack PC, Crowley JJ, Gandara DR. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). *J Thorac Oncol* 1(9):996-1001, 2006.
- Mulshine JL, Avila RS, **Hirsch FR (TOP,DT)**, Yankelevitz D. Developing CT image-processing tools to accelerate progress in lung cancer drug development. *Oncology (Williston Park)* 20(12):1606, 1608-1610, 1614, 2006.
- + **Nana-Sinkam SP (TOP), Geraci MW (TOP)**. MicroRNA in lung cancer. *J Thorac Oncol* 1(9):929-931, 2006.
- *+ **Schefter TE (DT), Kavanagh BD (DT), Raben D (TOP,DT), Kane M (TOP,DT), Chen C, Stuhr K, Kelly K, Mitchell JD (TOP), Bunn PA (TOP), Gaspar LE (TOP)**. A phase I/II trial of stereotactic body radiation therapy (SBRT) for lung metastases: Initial report of dose escalation and early toxicity. *Int J Radiat Oncol Biol Phys* 66(4 Suppl):S120-S127, 2006.
- Schonbrun E, Wu Q, **Park W (TOP)**, Yamashita T, Summers CJ. Polarization beam splitter based on a photonic crystal heterostructure. *Opt Lett* 31(21):3104-3106, 2006.
- Schwer AL, **Gaspar LE (TOP)**. Update in the treatment of brain metastases from lung cancer. *Clin Lung Cancer* 8(3):180-186, 2006.
- Thomas SM, Bholra NE, Zhang Q, Contrucci SC, Wentzel AL, Freilino ML, Gooding WE, Siegfried JM, **Chan DC (DT,TOP)**, Grandis JR. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. *Cancer Res* 66(24):11831-11839, 2006.
- Thunnissen FB, Kerr KM, Brambilla E, Comin CE, **Franklin WA (TRM)**, Gulldhammer B, Westra WH, Flieder DB. EU-US pathology panel for uniform diagnosis in randomised controlled trials for CT screening of lung cancer. *Eur Respir J* 28(6):1186-1189, 2006.
- *+ Travis WD, **Garg K (TOP), Franklin WA (TOP)**, Wistuba II, Sabloff B, Noguchi M, Kakinuma R, Zakowski M, Ginsberg M, Padera R, Jacobson F, Johnson BE, **Hirsch F (TOP,DT)**, Brambilla E, Flieder DB, Geisinger KR, Thunnissen F, Kerr K, Yankelevitz D, Franks TJ, Galvin JR, Henderson DW, Nicholson AG, Hasleton PS, Roggli V, Tsao MS, Cappuzzo F, Vazquez M. Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. *J Thorac Oncol* 1(9 Suppl):S13-S19, 2006.
- Varella-Garcia M (TOP)**, Chen L, Zheng X, Yu L, Dixon D. Karyotypic characteristics of human uterine leiomyoma and myometrial cell lines following telomerase induction. *Cancer Genet Cytogenet* 170(1):71-75, 2006.
- * Weiss GJ, **Bunn PA Jr (TOP), Camidge DR (DT)**. From radiotherapy to targeted therapy: 20 years in the management of non-small-cell lung cancer. *Oncology (Williston Park)* 20(12):1515-1524, 2006.

2007

- * Ballonoff A, **Kavanagh B (DT)**, Nash R, **Drabkin H (TOP,CB)**, Trotter J, **Rabinovitch R (HRM)**. Hodgkin lymphoma-related vanishing bile duct syndrome and idiopathic cholestasis, recovery of liver function with eradication of lymphoma: A case report and review of the world's literature. *Acta Oncologica*, in press, 2007.
- Belinsky SA, Grimes MJ, Casas E, Stidley CA, **Franklin WA (TOP)**, Bocklage TJ, Johnson DH, Schiller JH. Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. *Br J Cancer* 96(8):1278-1283, 2007.
- *+ **Bemis LT (CC)**, **Robinson WA (DT)**, McFarlane R, Buyers E, **Kelly K (TOP)**, **Varella-Garcia M (TOP)**, **Mitchell JD (TOP)**, **Franklin WA (TOP)**. EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome. *Lancet Oncol* 8(6):559-560, 2007.
- Binetruy B, **Heasley L (TOP)**, Bost F, Caron L, Aouadi M. Concise review: regulation of embryonic stem cell lineage commitment by mitogen-activated protein kinases. *Stem Cells* 25(5):1090-1095, 2007.
- Bunn PA Jr (TOP)**. Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors? *J Clin Oncol* 25(18):2504-2505, 2007.
- *+ **Byers T (PC)**, Wolf H, **Franklin WA (TOP)**, Broderick S, **Merrick D (TOP)**, **Shroyer K (HRM)**, **Hirsch FR (TOP,DT)**, Zeng C, **Barón AE (DT)**. Sputum cytologic atypia predicts incident lung cancer: Assessments of latency and histologic specificity. *Cancer Epidemiol Biomark Prev*, in press, 2007.
- * Cappuzzo F, Ligorio C, Toschi L, Rossi E, Trisolini R, Paioli D, Magrini E, Finocchiaro G, Bartollini S, Cancellieri A, **Hirsch FR (TOP,DT)**, Crino L, **Varella-Garcia M (TOP)**. EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). *J Thorac Oncol* 2(5):423-429, 2007.
- Cappuzzo F, Ligorio C, Janne PA, Toschi L, Rossi E, Trisolini R, Paioli D, Holmes AJ, Magrini E, Finocchiaro G, Bartolini S, Cancellieri A, Ciardiello F, Patelli M, Crino L, **Varella-Garcia M (TOP)**. Prospective study of gefitinib in epidermal growth factor receptor fluorescence *in situ* hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. *J Clin Oncol* 25(16):2248-2255, 2007.
- Chadman KK, Woods JH, **Stitzel J (TOP)**. Chlorisondamine inhibits the nicotine-induced stimulation of c-fos in the pigeon brain for up to 2 weeks. *Nicotine Tob Res* 9(9):927-936, 2007.
- *+ Chen C, **Kane MA (TOP,DT)**, **Song J (TOP)**, Campana J, Raben A, Harrison L, Quon H, Dancey J, **Baron A (DT)**, Said S, **Eckhardt SG (DT)**, **Raben D (TOP,DT)**. A phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. *J Clin Oncol* P, in press, 2007.
- Ding M, Newman F, Chen C, Stuhr K, **Gaspar LE (TOP)**. Dosimetric comparison between 3D-CRT and IMRT using different multileaf collimators in the treatment of brain tumors. *Med Dosim*, in press, 2007.

- *+ Dziadziuszko R, Holm B, Skov BG, Osterlind K, Sellers MV, **Franklin WA (TOP)**, **Bunn PA Jr (TOP)**, **Varella-Garcia M (TOP)**, **Hirsch FR (TOP,DT)**. Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. *Ann Oncol* 18(3):447-452, 2007.
- *+ Dziadziuszko R, Siemiatkowska A, Limon J, Rzyman W, Jassem J, **Bunn PA Jr (TOP)**, **Varella-Garcia M (TOP)**, **Hirsch FR (TOP,DT)**. Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report. *J Thorac Oncol* 2(1):91-92, 2007.
- Emerson SS, **Kittelson JM (TOP)**, Gillen DL. Frequentist evaluation of group sequential clinical trial designs. *Stat Med*, in press, 2007.
- Emerson SS, **Kittelson JM (TOP)**, Gillen DL. Bayesian evaluation of group sequential clinical trial designs. *Stat Med* 26(7):1431-1449, 2007.
- Franklin WA (TOP)**. RAGE in lung tumors. *Am J Respir Crit Care Med* 175(2):106-107, 2007.
- + Frazer-Abel AA, **McCue JM (TOP)**, Lazis S, Portas M, Lambert C, **Freed BM (TOP)**. Cigarette tar phenols impede T cell cycle progression by inhibiting cyclin-dependent kinases. *Mol Immunol* 44(4):488-493, 2007.
- *+ Frederick BA, Helfrich BA, **Coldren CD (TOP)**, Zheng D, **Chan D (DT,TOP)**, **Bunn PA Jr (TOP)**, **Raben D (TOP,DT)**. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. *Mol Cancer Ther* 6(6):1683-1691, 2007.
- Gandara DR, Davies AM, Gautschi O, Mack PC, Lau DH, Lara PN Jr, **Hirsch FR (TOP,DT)**. Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies. *Clin Lung Cancer* 8(Suppl 2):S61-S67, 2007.
- Garfield D (TOP)**, Hercbergs A, Davis PJ. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. *J Natl Cancer Inst* 99(12):975-976, 2007.
- Garfield D (TOP)**, Cadranet JL. Possible mechanism(s) of action of bortezomib in a patient with bronchioloalveolar carcinoma. *Lung Cancer* 57(2):249-250, 2007.
- Gaspar LE (TOP)**. Stereotactic body radiation therapy for lung tumors: system-related issues and complications. *Clin Lung Cancer* 8(4):233, 2007.
- + Gingo MR, Silveira LJ, **Miller YE (TOP)**, Friedlander AL, Cosgrove GP, Chan ED, Maier LA, **Bowler RP (TOP)**. Tumor necrosis factor gene polymorphisms are associated with chronic obstructive pulmonary disease. *Eur Respir J*, in press, 2007.
- * **Gustafson DL (DT)**, Frederick B, Merz AL, **Raben D (TOP,DT)**. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima((R))) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. *Cancer Chemother Pharmacol*, in press, 2007.

- + **Heasley L (TOP), Winn RA (TOP)**. Analysis of Wnt7a-stimulated JNK activity and cJun phosphorylation in non-small cell lung cancer cells. *Methods Mol Biol*, in press, 2007.
- *+ **Hirsch FR (TOP,DT), Varella-Garcia M (TOP)**, Cappuzzo F, McCoy J, Bemis L (CC), Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar AF, Crino L, Gandara DR, **Franklin WA (TOP), Bunn PA Jr (TOP)**. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. *Ann Oncol* 18(4):752-760, 2007.
- *+ **Hirsch FR (TOP,DT)**, Dziadziuszko R, Thatcher N, Mann H, Watkins C, Parums D, Speake G, Holloway B, **Bunn PA Jr (TOP), Franklin WA (TOP)**. Epidermal growth factor receptor immunohistochemistry: Comparison of antibodies and cut-off points to predict benefit from Gefitinib in a Phase III placebo-controlled study in advanced non-small cell lung cancer. *Cancer*, in press, 2007.
- * Hutchison KE, Allen DL, Filbey FM, Jepson C, Lerman C, Benowitz NL, **Stitzel J (TOP), Bryan A (PC)**, McGeary J, Haughey HM. CHRNA4 and tobacco dependence: From gene regulation to treatment outcome. *Arch Gen Psychiatry* 64(9):1078-1086, 2007.
- * Irwin D, Helm K, Campbell N, Imamura M, Fagan KA, Harral J, Carr M, Young KA, Klemm DJ, Gebb SA, **Dempsey EC (TOP)**, West J, **Majka SM (CB)**. Neonatal lung side population cells demonstrate endothelial potential and are altered in response to hyperoxia induced lung simplification. *Am J Physiol Lung Cell Mol Physiol*, in press, 2007.
- *+ Jonsson S, **Varella-Garcia M (TOP), Miller YE (TOP)**, Wolf HJ, **Byers T (PC)**, Braudrick S, Kiatsimkul P, Lewis M, **Kennedy TC (TOP), Keith RL (TOP)**, Bjornsson J, McWilliams A, Lam S, **Hirsch FR (TOP,DT), Franklin WA (TOP)**. Chromosomal aneusomy in bronchial high grade lesions is associated with invasive lung cancer. *Am J Respir Crit Care Med*, in press, 2007.
- *+ **Kavanagh BD (DT), Kelly K (TOP), Kane M (TOP,DT)**. The promise of stereotactic body radiation therapy in a new era of oncology. *Front Radiat Ther Oncol* 40340-351, 2007.
- Kennedy TC (TOP)**, McWilliams A, Edell E, Sutedja T, Downie G, Yung R, Gazdar A, Mathur PN. Bronchial intraepithelial neoplasia/early central airways lung cancer: ACCP Evidence-based clinical practice guidelines (2nd ed). *Chest* 132221S-233S, 2007.
- Lambert C, Li J, Jonscher K, Yang TC, Reigan P, Quintana M, Harvey J, **Freed BM (TOP)**. Acrolein inhibits cytokine gene expression by alkylating cysteine and arginine residues in the NF-kappaB1 DNA binding domain. *J Biol Chem* 282(27):19666-19675, 2007.
- Li XC, Karadsheh MS, Jenkins PM, Brooks JC, Drapeau JA, Shah MS, Lautner MA, **Stitzel JA (TOP)**. Chromosomal loci that influence oral nicotine consumption in C57BL/6J x C3H/HeJ F2 intercross mice. *Genes Brain Behav* 6(5):401-410, 2007.
- Little AG, Gay EG, **Gaspar LE (TOP)**, Stewart AK. National survey of non-small cell lung cancer in the United States: Epidemiology, pathology and patterns of care. *Lung Cancer* 57(3):253-260, 2007.

- Massarelli E, **Varella-Garcia M (TOP)**, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, Wistuba II. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. *Clin Cancer Res* 13(10):2890-2896, 2007.
- Mexal S, Jenkins PM, Lautner MA, Jacob E, Crouch EL, **Stitzel JA (TOP)**. alpha7 nicotinic receptor gene promoter polymorphisms in inbred mice affect expression in a cell type-specific fashion. *J Biol Chem* 282(18):13220-13227, 2007.
- *+ **Miller YE (TOP)**, Blatchford P, Hyun DS, **Keith RL (TOP)**, **Kennedy TC (TOP)**, Wolf H, **Byers T (PC)**, **Bunn PA Jr (TOP)**, Lewis MT, **Franklin WA (TOP)**, **Hirsch FR (TOP,DT)**, **Kittelson J (TOP)**. Bronchial epithelial Ki-67 index is related to histology, smoking and gender but not lung cancer or chronic obstructive pulmonary disease. *Cancer Epidemiol Biomarkers Prev*, in press, 2007.
- + **Miller YE (TOP)**, **Keith RL (TOP)**. Inhaled corticosteroids and lung cancer chemoprevention. *Am J Respir Crit Care Med* 175(7):636-637, 2007.
- Morissette G, Houle S, Gera L, **Stewart JM (TOP)**, Marceau F. Antagonist, partial agonist and antiproliferative actions of B-9870 (CU201) as a function of the expression and density of the bradykinin B(1) and B(2) receptors. *Br J Pharmacol* 150(3):369-379, 2007.
- + **Nana-Sinkam SP (TOP)**, Lee JD, Sotto-Santiago S, **Stearman RS (TOP)**, **Keith RL (TOP)**, **Choudhury Q (TOP)**, Cool C, Parr J, Moore MD, Bull TM, **Voelkel NF (TOP)**, **Geraci MW (TOP)**. Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke. *Am J Respir Crit Care Med* 175(7):676-685, 2007.
- Nemenoff RA (CB,TOP)**. Peroxisome proliferator-activated receptor-gamma in lung cancer: Defining specific versus "off-target" effectors. *J Thorac Oncol*, in press, 2007.
- * Peebles KA, **Dwyer-Nield LD (CC)**, **Malkinson AM (CC,TOP)**. Altered expression of splicing factor, heterogeneous nuclear ribonucleoprotein A2/B1, in mouse lung neoplasia. *Mol Carcinog* 46(11):887-900, 2007.
- Pervez H, **Kane MA (TOP,DT)**. Chemotherapy-induced neutropenia. *Federal Practitioner*, in press, 2007.
- *+ Potiron VA, **Sharma G (TOP)**, Nasarre P, Clarhaut JA, Augustin HG, **Gemmill RM (CB)**, Roche J, **Drabkin HA (TOP,CB)**. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. *Cancer Res* 67(18):8708-8715, 2007.
- Pugh TJ, **Gaspar LE (TOP)**. Prophylactic cranial irradiation for patients with lung cancer. *Clin Lung Cancer* 8(6):365-368, 2007.
- * Redente EF, **Orlicky DJ (HRM)**, Bouchard RJ, **Malkinson AM (CC,TOP)**. Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethane-induced primary lung tumorigenesis in A/J mice. *Am J Pathol* 170(2):693-708, 2007.

- Rusthoven K, **Raben D (TOP,DT)**, Chen C. Improved survival in patients with stage III-IV head and neck squamous cell carcinoma treated with radiotherapy as the primary local treatment modality. *Int J Radiat Oncol Biol Phys*, in press, 2007.
- * Rusthoven K, Chen C, **Raben D (TOP, DT)**, **Kavanagh B (DT)**. Use of external beam radiotherapy is associated with a reduced incidence of second primary head and neck cancers: a SEER database analysis. *Int J Radiat Oncol Biol Phys*, in press, 2007.
- *+ Rusthoven KE, **Raben D (TOP,DT)**, Ballonoff A, **Kane MA (TOP,DT)**, **Song JI (TOP)**, Chen C. Comparison of three radiotherapy techniques with concurrent systemic therapy for stage III-IV squamous cell carcinoma of the oropharynx. *Laryngoscope*, in press, 2007.
- Sakao S, Taraseviciene-Stewart L, Cool CD, Tada Y, Kasahara Y, Kurosu K, Tanabe N, Takiguchi Y, Tatsumi K, Kuriyama T, **Voelkel NF (TOP)**. VEGF-R blockade causes endothelial cell apoptosis, expansion of surviving CD34+ precursor cells and transdifferentiation to smooth muscle-like and neuronal-like cells. *FASEB J*, in press, 2007.
- * Schwer AL, **Damek DM (II)**, **Kavanagh BD (DT)**, **Gaspar LE (TOP)**, **Lillehei K (II)**, Stuhr K, Chen C. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. *Int J Radiat Oncol Biol Phys*, in press, 2007.
- Solomon B, **Bunn PA Jr (TOP)**. Adjuvant chemotherapy for non-small cell lung cancer. *Cancer Invest* 25(4):217-225, 2007.
- Sperduto PW, Berkey B, **Gaspar LE (TOP)**, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1960 patients in the RTOG Database. *Int J Radiat Oncol Biol Phys*, in press, 2007.
- *+ **Stearman RS (TOP)**, **Dwyer-Nield L (CC)**, Grady MC, **Malkinson AM (CC,TOP)**, **Geraci MW (TOP)**. A unique macrophage gene expression signature defines a field effect in the lung tumor microenvironment. *Cancer Res*, in press, 2007.
- + **Stearman RS (TOP)**, Grady MC, **Nana-Sinkam P (TOP)**, **Varella-Garcia M (TOP)**, **Geraci MW (TOP)**. Genetic and epigenetic regulation of the human prostacyclin synthase promoter in lung cancer cell lines. *Mol Cancer Res* 5(3):295-308, 2007.
- * **Stringer KA (TOP)**, Tobias M, O'Neill HC, **Franklin CC (CC)**. Cigarette smoke extract-induced suppression of caspase-3-like activity impairs human neutrophil phagocytosis. *Am J Physiol Lung Cell Mol Physiol* 292(6):L1572-L1579, 2007.
- *+ Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsy-pin M, **Hunsucker SW (CB)**, Caprioli R, **Duncan MW (MOP)**, **Hirsch FR (TOP,DT)**, **Bunn PA Jr (TOP)**, Carbone DP. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. *J Natl Cancer Inst* 99(11):838-846, 2007.
- *+ **Varella-Garcia M (TOP)**, Chen L, Powell RL, **Hirsch FR (TOP,DT)**, **Kennedy TC (TOP)**, **Keith R (TOP)**, **Miller YE (TOP)**, **Mitchell JD (TOP)**, **Franklin WA**

- (TOP)**. Spectral karyotyping detects chromosome damage in bronchial cells of smokers and patients with cancer. *Am J Respir Crit Care Med* 176(5):505-512, 2007.
- * Vikis H, Sato M, James M, Wang D, Wang Y, **Wang M (CB)**, Jia D, Liu Y, Bailey-Wilson JE, Amos CI, Pinney SM, Petersen GM, de Andrade M, Yang P, Wiest JS, **Fain PR (TOP)**, Schwartz AG, Gazdar A, Gaba C, Rothschild H, Mandal D, Kupert E, Seminara D, Viswanathan A, Govindan R, Minna J, Anderson MW, You M. EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. *Cancer Res* 67(10):4665-4670, 2007.
- Wang J, Edeen K, Manzer R, Chang Y, Wang S, Chen X, Funk CJ, Cosgrove GP, Fang X, **Mason RJ (TOP)**. Differentiated human alveolar epithelial cells and reversibility of their phenotype *in vitro*. *Am J Respir Cell Mol Biol* 36(6):661-668, 2007.
- * **Wang M (CB)**, Vikis HG, Wang Y, Jia D, Wang D, Bierut LJ, Bailey-Wilson JE, Amos CI, Pinney SM, Petersen GM, de Andrade M, Yang P, Wiest JS, **Fain PR (TOP)**, Schwartz AG, Gazdar A, Minna J, Gaba C, Rothschild H, Mandal D, Kupert E, Seminara D, Liu Y, Viswanathan A, Govindan R, Anderson MW, You M. Identification of a novel tumor suppressor gene p34 on human chromosome 6q25.1. *Cancer Res* 67(1):93-99, 2007.
- + Wang W, Zolty E, Falk S, Summer S, **Stearman R (TOP)**, **Geraci MW (TOP)**, Schrier RW. Prostacyclin in endotoxemia-induced acute kidney injury: Cyclooxygenase inhibition and renal prostacyclin synthase transgenic mice. *Am J Physiol Renal Physiol*, in press, 2007.
- Weiss GJ, Vokes EE, **Bunn PA Jr (TOP)**, Magree L, Rusk J, Albert D, Kelly K. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: A multicenter, phase II clinical trial. *J Thorac Oncol*, in press, 2007.
- + Weiss GJ, Zeng C, **Kelly K (TOP)**, Tran ZV, **Bunn PA Jr (TOP)**. Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer. *Clin Lung Cancer* 8(5):335-338, 2007.
- Weiss GJ, Rosell R, Fossella F, Perry M, Stahel R, Barata F, Nguyen B, Paul S, McAndrews P, Hanna N, Kelly K, **Bunn PA Jr (TOP)**. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. *Ann Oncol* 18(3):453-460, 2007.
- *+ Willey CD, Murphy BA, Netteville JL, Burkey BB, Shyr Y, Shakhtour B, Kish B, **Raben D (TOP,DT)**, Chen C, **Song JI (TOP)**, **Kane MA (TOP,DT)**, Cmelak AJ. A phase II multi-institutional trial of chemoradiation using weekly docetaxel and erythropoietin for high-risk postoperative head and neck cancer patients. *Int J Radiat Oncol Biol Phys* 67(5):1323-1331, 2007.
- Zhou W, Hashimoto K, Goleniewska K, O'Neal JF, Ji S, Blackwell TS, Fitzgerald GA, Egan KM, **Geraci MW (TOP)**. Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells. *J Immunol* 178(2):702-710, 2007.